RECEIVED CENTRAL FAX CENTER

T-046 P.01

FAX TRANSMISSION
Company of the property of the
DATE: March 7, 2005
PTO IDENTIFIER: Application Number 09/972772-Conf #1878
Patent Number Inventor: Gary L. OLSON et al.
MESSAGE TO: US Patent and Trademark Office
FAX NUMBER: (703) 872-9306
FROM: LAHIVE & COCKFIELD, LLP
Maria Laccotripe Zacharakis, Ph.D., J.D.
PHONE: (617) 227-7400
Attorney Dkt. #: PPI-106CP
PAGES (Including Cover Sheet): 25
CONTENTS: Amendment Transmittal (1 page) Amendment After Final Action (37 C.F.R. Section 1.116) (21 pages)
If your receipt of this transmission is in error, please notify this firm immediately by collect call to sender at (617) 227-7400 and send the original transmission to us by return mail at the address below.
This transmission is intended for the sole use of the individual and entity to whom it is addressed, and may contain information that is privileged, confident and exempt from disclosure under applicable law. You are hereby notified that any dissemination, distribution or duplication of this transmission by someone other than the intended addressee or its designated agent is strictly prohibited
LAHIVE & COCKFIELD, LLP 28 State Street Boston, Massachusetts 02109 Telephone: (617) 227-7400 Facsimile: (617) 742-4214

AMENDMENT TRANSMITTAL LETTER								PPI-106CP		
Application No Filing Date Examiner						aminer		Art Unit		
09/972772-Conf. #4878			October 5, 2001		J E. Russel			1654		
Applicant(s): Gary L. OLSON et al.										
nv	THERAPEUTIC AGENTS AND METHODS OF USE THEREOF FOR THE MODULATION OF ANGIOGENESIS									
TO THE COMMISSIONER FOR PATENTS										
Transmitted nerewith is an amendment in the above-identified application.										
The fee has been calculated and is transmitted as shown below.										
CLAIMS AS AMENDED										
		Claims Remaining After Amendment	Highest Number Previously Paid	Number Extra Claims Present	Rat	*				
	Total Claims	59	- 68 =		х					
	Independent	8	- 8 =		×					
İ	Multiple Dependent Claims (check if applicable)									
	Other fee (please specify): TOTAL ADDITIONAL FEE FOR THIS AMENDMENT:									
Small Entity										
Large Entity										
No additional fee is required for this amendment.										
Please charge Deposit Account No. 12-0080 In the amount of \$ A duplicate copy of this sheet is enclosed.										
A check in the amount of \$ to cover the filing fee is enclosed. Payment by credit card. Form PTO-2038 is attached										
The Director is hereby authorized to charge and credit Deposit Account No. 12-0080 as described below A duplicate copy of this sheet is enclosed.										
		any overpayme								
				tion processing	a fees requi	red under	37 CFR	1.16 and 1.17		
Charge any additional filing or application processing fees required under 37 CFR 1.16 and 1.17										
Acrotyle Dated: March 7, 2005										
Maria Laccotripe Zacharakis, Ph.D., J.D. Attorney Reg. No. 56,266										
	28 State Stree	achusetts 021								
I hereby certify that this correspondence is being facsimal transmitted to the Patent and Trademark Office, facsimile no. (703) 872- 9306 at MS AF, Commissioner for Patents, P.O. Box 450, Assandra, VA 22313-450, on the date shown below.										
	Dated March 7, 2005 Signature.									
H										

I hereby centry that this correspondence is being facsimile transmitted to the Patent and Trademark Office, facsimile no. (703) 872-8305 at MS AF. Commissioner for Patents, P O Box 1450, Alexandra, VA 22313-1450 in the date shown below

Dated: March 7, 2005 Signature

Docket No.: PPI-106CP

(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

Gary L. Olson et al.

RECEIVED

Application No.: 09/972772

Confirmation No.: 4878 CENTRAL FAX CENTER

Art Unit: 1654

MAR 0 7 2005

Filed: October 5, 2001

Examiner: J. E. Russel

For: THERAPEUTIC AGENTS AND METHODS OF USE THEREOF FOR THE MODULATION

OF ANGIOGENESIS

AMENDMENT AFTER FINAL ACTION (37 C.F.R. SECTION 1.116)

MS AF Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

INTRODUCTORY COMMENTS

Responsive to the Office Action dated December 6, 2004, finally rejecting claims 1-43, 45-48, and 50-61, please amend the above-identified U.S. patent application as follows.

Amendments to the Specification begin on page 2 of this paper.

Amendments to the Claims are reflected in the listing of claims which begins on page 3 of this paper.

Remarks/Arguments begin on page 18 of this paper.